Active, not recruitingNot applicableNCT03739372
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
Studying Diffuse astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, San Francisco
- Principal Investigator
- Sabine Mueller, MD, PhD, MAS, MD, PhDUniversity of California, San Francisco
- Intervention
- Specialized tumor board recommendation(other)
- Enrollment
- 44 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2018 – 2027
Study locations (12)
- University of California, San Diego Rady Children's Hospital, San Diego, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Children's Hospitals and Clinics of Minneapolis, Minneapolis, Minnesota, United States
- Washington University, St Louis, Missouri, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- The Children's Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- Seattle Children's Hospital, Seattle, Washington, United States
Collaborators
Pacific Pediatric Neuro-Oncology Consortium · The V Foundation for Cancer Research
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03739372 on ClinicalTrials.govOther trials for Diffuse astrocytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT04729959Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE4NCT03975829Pediatric Long-Term Follow-up and Rollover StudyNovartis Pharmaceuticals